Evidence map›Paper›PMID 39189434›Full record

ArticleJournal of magnetic resonance imaging : JMRI2025

Wilfried Reichardt, Tabea Gewalt, Philipp Hafner, Steffen J Keller, Xun Chen, Asma Alrawashdeh, Yayu Li, Solène Besson, Stefan Fichtner-Feigl, Dominik von Elverfeldt and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wilfried ReichardtDivision of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Tabea GewaltDivision of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Philipp HafnerDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Steffen J KellerDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Xun ChenDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Asma AlrawashdehDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Yayu LiDivision of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Solène BessonDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID https://orcid.org/0000-0002-0705-6491
Stefan Fichtner-FeiglDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Dominik von ElverfeldtDivision of Medical Physics, Department of Diagnostic and Interventional Radiology, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Huda JumaaDepartment of General and Visceral Surgery, Center for Surgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Dietrich A RuessGerman Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany.ORCID https://orcid.org/0000-0003-4371-2246

Funding

Deutsche Forschungsgemeinschaft CRC1479-441891347Deutsche Krebshilfe 70113697
6 · The paper itself

Abstract

backgroundPancreatic cancer has a poor prognosis. Targeting Kirsten Rat Sarcoma (KRAS) mutation and its related pathways may enhance immunotherapy efficacy. While in vivo monitoring of therapeutic response and immune cell migration remains challenging, Fluorine-19 MRI ( PURPOSE: Evaluating the potential of STUDY TYPE: Pre-clinical animal study. ANIMAL MODEL: Murine genetically engineered pancreatic cancer model (N = 20, both sexes). FIELD STRENGTH/SEQUENCE: 9.4-T, two-dimensional multi-slice Rapid Acquisition with Relaxation Enhancement sequence. Intravenous injection of ASSESSMENT: Upon tumor detection by conventional STATISTICAL TESTS: Independent t-tests and one-way analysis of variance.

resultsDATA

conclusionEVIDENCE LEVEL: 1 TECHNICAL EFFICACY: Stage 2.

Indexed as

Fluorine-19 Magnetic Resonance ImagingMagnetic Resonance ImagingPancreatic NeoplasmsTumor MicroenvironmentAnimalsDisease Models, AnimalFemaleFluorocarbonsMaleMiceNanoparticlesPiperidinesProtein Tyrosine Phosphatase, Non-Receptor Type 11PyridonesPyrimidinonesFluorocarbonsPiperidinesProtein Tyrosine Phosphatase, Non-Receptor Type 11PyridonesPyrimidinonestrametinib19Fluorine‐MRIimmuno‐microenvironment‐monitoringKRASpancreatic cancer

Identifiers

PMID39189434
PMCPMC11896934

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.